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osting by EAbstract The reaction of anthrone 1 with 4-aminoantipyrine and thiosemicarbazide afforded
4-(anthracen-9(10H)-ylideneamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one 2 and an-
thracen-9(10H)-one thiosemicarbazone 5, respectively. Oxidation of compound 2 with potassium
permanganate gave 4-(anthracen-9(10H)-ylideneamino)-1-methyl-3-oxo-2-phenyl-2,3-dihydro-1H
pyrazole-5-carboxylic acid 3 which on reaction with o-phenylenediamine gave 4-(anthracen-
9(10H)-ylideneamino)-5-(1H-benzimidazol-2-yl)-1-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
4. Furthermore, compound 5 was condensed with different substituted phenacyl bromide to give
a series of 2-(anthracen-9(10H)-ylidenehydrazono)-5-substituted-2,3-dihydro-1H-thiazole 6a–g.
Compound 5 also reacted with chloroacetic acid affording 2-(anthracen-9(10H)-ylidenehydrazon-
o)thiazolidin-4-one 7. The structures of all the products have been determined by elemental analysis
and spectral studies. All compounds have been screened for their antibacterial and antifungal stud-
ies. The results are summarized in Tables 1 and 2.
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lsevier1. Introduction
Research and development of potent and effective antimicro-
bial agents represents one of the most important advances in
therapeutics, not only in the control of serious infections,
but also in the prevention and treatment of some infectious
complications of other therapeutic modalities such as cancer
chemotherapy and surgery. Over the past decade, fungal infec-
tion became an important complication and a major cause of
morbidity and mortality in immuno-compromised individuals
such as those suffering from tuberculosis, cancer or AIDS
and in organ transplant cases (Turan-Zitouni et al., 2005).
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addressing the problem of multi-drug resistant (MDR) bacte-
ria and fungi resulting from the widespread use and misuse
of classical antimicrobial agents (Akbas and Berber, 2005).
Such serious global health problem demands a renewed effort
seeking the development of new antimicrobial agents effective
against pathogenic microorganisms resistant to currently avail-
able treatments.
Antibacterial and antifungal activities of the azoles are the
most widely studied and some of them are in clinical practice
as antimicrobial agents. However, the azole-resistant strains
led to the development of a new antimicrobial compounds.
In particular pyrazole derivatives are extensively studied and
used as antimicrobial agents. Pyrazole is an important class
of heterocyclic compounds and many pyrazole derivatives
are reported to have a broad spectrum of biological activities,
such as anti-inﬂammatory, antifungal (Prakash et al., 2008),
herbicidal (Kudo et al., 1999), antitumour, cytotoxic, molecu-
lar modelling (Vera-DiVaio et al., 2009), and antiviral (Storer
et al., 1999) activities. Pyrazole derivatives also acts as antian-
giogenic agents (Qiao et al., 2004), A3 adenosine receptor
antagonists (Baraldi et al., 2003), neuropeptide YY5 receptor
antagonists (Stamford and Wu, 2004), kinase inhibitor for
treatment of type 2 diabetes, hyperlipidemia, obesity (Brown
et al., 2004), and thrombopiotinmimetics (Heerding, 2004).
Antipyrine (2,3-dimethyl-1-phenyl-3-pyrazolin-5-one) was
the ﬁrst pyrazolone derivative used in the management of pain
and inﬂammation, and their derivatives have attracted the
attention of several research groups due to their potential
activities (Jain et al., 2003). In this context, broad spectra of
bioactive antipyrine derivatives have been investigated and
diversities of bioactivities such as analgesic (Filho et al.,
1998), anti-inﬂammatory (Ismail et al., 2007), antimicrobial
(Mishra, 1999), and anticancer activity (Sondhi et al., 2001)
have been reported. The antibacterial activity caught our
attention because antimicrobial resistance developed by impor-
tant pathogens has increased in the last decade (Sutcliffe,
2003). Besides, emerging and re-emerging bacterial infectious
diseases still cause death and disability worldwide (Morens
et al., 2004).
Benzimidazoles are remarkably effective compounds both
with respect to their inhibitory activity and their favorable
selectivity ratio. Extensive biochemical and pharmacological
studies have conﬁrmed that benzimidazole molecules are effec-
tive against various strains of microorganisms (Kazimierczuk
et al., 2002). Benzimidazoles are regarded as a promising class
of bioactive heterocyclic compounds that exhibit a range of
biological activities. Speciﬁcally, this nucleus is a constituent
of vitamin-B12 (O´niel et al., 2001). This ring system is present
in numerous antioxidant (Ayhan-Kilcigil et al., 2007), antipar-
asitic (Navarrete-Vazquez et al., 2001), antihelmintics (Ravina
et al., 1993), antiproliferative (Garuti et al., 2000), and anti-
HIV (Rao et al., 2002) activities.
Thiazolidin-4-ones are an important group of heterocyclic
compounds, having valuable biological activities in the areas
of medicine. Recently, antimicrobial and antimycobacterial
activities (de Aquino et al., 2008; Verma and Saraf, 2008;
Ku¨c¸u¨kgu¨zel et al., 2006) of this framework containing com-
pounds were explored well whereas their 2,3-disubstituted ana-
logues have proved to be predominantly effective non-
nucleoside HIV reverse transcriptase inhibitors (Barreca
et al., 2001). Likewise, thiazole and their 2-substituted deriva-tives were also reported to exhibit diverse biological properties
such as antituberculous and antimicrobial activities (Karegou-
dar et al., 2008). Moreover, it has been found in the drug devel-
opment program for the treatment of inﬂammation
(Suryavanshi and Pai, 2006) and HIV (Balzarini et al., 2009).
In view of the above-mentioned ﬁndings and as a continu-
ation of our efforts (Salimon and Salih, 2010) to identify new
candidates that may be of value in designing new, potent,
selective and less toxic antimicrobial agents, we report herein
the synthesis of some new heterocyclic derivatives starting
from anthrone in order to investigate their antimicrobial activ-
ity (Fig. 1).2. Experimental
2.1. Measurements
Melting points were determined in open glass capillaries on a
Gallenkamp apparatus and are uncorrected. The percentage
compositions of the elements (CHNS) for the compounds were
determined using an elemental analyzer CHNS Model Fison
EA 1108. The infrared spectra were recorded as potassium
bromide discs using a Perkin-Elmer spectrophotometer GX.
The 1H and 13C nuclear magnetic resonance spectra were re-
corded using the JEOL JNM-ECP 400 spectrometer in
DMSO-d6 as the solvent, using TMS as an internal standard,
and chemical shifts are expressed as dppm. All the reactions
were followed by TLC (Silica gel, aluminum sheers 60 F254,
Merck).
2.2. Synthesis of of 4-(anthracen-9(10H)-ylideneamino)-1,5-
dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (2)
A mixture of anthrone 1 (10.5 g, 0.012 mol), 30 mL glacial ace-
tic acid and 4-aminoantipyrine (8.76 g, 0.012 mol) was heated
under reﬂux for 10 h. The reaction mixture was ﬁltered off
and recrystalized from ethanol (5.43 g, 55%); mp 67–69 C;
IR (KBr) cm1 3089 (C–H aromatic), 2954, 2824 (C–H ali-
phatic), 1678 (C‚O), 1621 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.67 (s, 3H, CH3), 2.05 (s, 2H, CH2),
8.11–8.17 (d, 1H, Ar–H), 7.94–8.03 (d, 1H, Ar–H), 7.55–7.64
(d, 1H, Ar–H), 7.51–7.65 (d, 1H, Ar–H), 7.24–7.33 (d, 1H,
Ar–H), 7.26–7.33 (d, 1H, Ar–H), 7.23–7.28 (t, 1H, Ar–H),
7.17–7.20 (t, 1H, Ar–H), 7.06–7.13 (t, 1H, Ar–H), 6.90–6.96
(t, 1H, Ar–H), 6.82–6.88 (t, 1H, Ar–H), 6.71–6.75 (t, 1H,
Ar–H), 6.66–6.69 (t, 1H, Ar–H).13C NMR (400 MHz-
DMSO-d6-ppm) d 13.05, 13.11 (2C, 2 CH3), 14.51 (1C,
CH2), 61.53 (1C, C‚N), 131.24–135.98 (18C, aromatic car-
bons), 166.70 (C, C‚O). Anal. Found (calc.) for C30H37N3O
(%): C, 79.09 (79.08); H, 8.20 (8.19); N, 9.23 (9.22).2.3. Synthesis of 4-(anthracen-9(10H)-ylideneamino)-1-
methyl-3-oxo-2-phenyl-2,3-dihydro-1H pyrazole-5-carboxylic
acid (3)
Compound 2 (20 g, 0.04 mol) is added to a solution of (6.32 g,
0.04 mol) of potassium permanganate and (3.32 g, 0.04 mol)
sodium carbonate in (85 mL) water and the mixture is heated
under reﬂux until the color of the permanganate has disap-
peared (15 h). The reaction mixture was ﬁltered while still
hot to get rid of the MnO2 precipitate. The cooled ﬁltrate is
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Fig. 1 Synthetic protocol to synthesis compounds (2–7).
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itate is ﬁltered off, washed with a little cold water and crystal-
lized from ethanol to give compound 3 as colorless crystals
(18 g, 58.4%); mp 193–195 C; IR (KBr) cm1 3425 (O–H),
3067 (C–H aromatic), 2987, 2865 (C–H aliphatic), 1718 and
1682 (C‚O), 1623 (C‚N). 1H NMR (400 MHz-DMSO-d6-
ppm) d 1.69 (s, 3H, CH3), 2.04 (s, 2H, CH2), 8.12–8.18 (d,
1H, Ar–H), 7.95–8.02 (d, 1H, Ar–H), 7.54–7.65 (d, 1H, Ar–
H), 7.52–7.64 (d, 1H, Ar–H), 7.25–7.32 (d, 1H, Ar–H), 7.25–
7.32 (d, 1H, Ar–H), 7.24–7.27 (t, 1H, Ar–H), 7.16–7.21 (t,
1H, Ar–H), 7.05–7.12 (t, 1H, Ar–H), 6.91–6.95 (t, 1H, Ar–
H), 6.83–6.89 (t, 1H, Ar–H), 6.72–6.76 (t, 1H, Ar–H), 6.65–
6.68 (t, 1H, Ar–H), 11.69 (br s, 1H, O–H, D2O exchangeable).
13C NMR (400 MHz-DMSO-d6-ppm) d 13.04 (1C, CH3),14.50 (1C, CH2), 61.54 (1C, C‚N), 131.23–135.97 (18C, aro-
matic carbons), 164.21, 171.30 (2C, 2 C‚O). Anal. Found
(calc.) for C30H35N3O3 (%): C, 74.23 (74.20); H, 7.25 (7.26);
N, 8.63 (8.65).
2.4. Synthesis of 4-(anthracen-9(10H)-ylideneamino)-5-(1H-
benzimidazol-2-yl)-1-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-
3-one (4)
To (10.8 g, 0.02 mol) of compound 3, a mixture of (2.16 g,
0.02 mol) o-phenylenediamine and a few drops of conc. hydro-
chloric acid in (100 mL) abs. ethanol was added. Then the mix-
ture was heated under reﬂux for 24 h, the completion of the
reaction was monitored by TLC. Cooled to room temperature
402 J. Salimon et al.and to the reaction mass was added 100 mL of water, stirred
for 2 h, and the solid obtained was ﬁltered and washed with
water. Crystallization from ethanol gave compound 4 as color-
less crystals (8.5 g, 83%); mp 120–122 C; IR (KBr) cm1 3356
(N–H), 3080 (C–H aromatic), 2924, 2841 (C–H aliphatic), 1683
(C‚O), 1628 (C‚N). 1H NMR (400 MHz-DMSO-d6-ppm) d
1.63 (s, 3H, CH3), 2.08 (s, 2H, CH2), 8.15–8.21 (d, 1H, Ar–H),
7.92–7.97 (d, 1H, Ar–H), 7.83–7.89 (d, 1H, Ar–H), 7.73–7.78
(d, 1H, Ar–H), 7.66–7.70 (d, 1H, Ar–H), 7.54–7.61 (m, 12H,
Ar–H), 8.69 (s, 1H, N–H, D2O exchangeable).
13C NMR
(400 MHz-DMSO-d6-ppm) d 12.89 (1C, CH3), 13.34 (1C,
CH2), 60.47 (1C, C‚N), 132.15–140.10 (14C, aromatic car-
bons), 169.23 (1C, C‚O). Anal. Found (calc.) for
C39H49N5O (%): C, 77.58 (77.57); H, 8.19 (8.18); N, 11.58
(11.60).
2.5. Synthesis of anthracen-9(10H)-one thiosemicarbazone (5)
Thiosemicarbazide (4.6 g, 0.05 mol) was added to (13 g,
0.05 mol) of anthrone 1 dissolved in glacial acetic acid
(100 mL), the reaction mixture was reﬂuxed for 10 h and the
completion of the reaction was monitored by TLC. Cooled
to room temperature and the reaction mass poured into
250 mL ice water, the solid obtained was ﬁltered, washed with
water, and recrystallized from methanol yielding 5 (11.3 g,
81.2%); mp 210–212 C; IR (KBr) cm1 3445 and 3350
(NH2), 3063 (C–H aromatic), 1620 (C‚N).
1H NMR
(400 MHz-DMSO-d6-ppm) d 1.89 (s, 2H, CH2), 8.10–8.13 (d,
1H, Ar–H), 7.98–8.04 (d, 1H, Ar–H), 7.85–7.89 (d, 1H, Ar–
H), 7.72–7.75 (d, 1H, Ar–H), 7.65–7.69 (t, 1H, Ar–H), 7.55–
7.60 (t, 1H, Ar–H), 7.46–7.50 (t, 1H, Ar–H), 7.38–7.42 (t,
1H, Ar–H), 9.38 (s, 2H, NH2, D2O exchangeable).
13C NMR
(400 MHz-DMSO-d6-ppm) d 11.05 (1C, CH2), 62.17 (1C,
C‚N), 130.41–136.25 (12C, aromatic carbons). Anal. Found
(calc.) for C19H25N3S (%): C, 69.67 (69.68); H, 7.65 (7.69);
N, 12.80 (12.83); S, 9.80 (9.79).
2.6. General synthesis procedure for compound (6a–g)
A mixture of compound 5 (3 g, 0.007 mol) and different p-
substituted phenacyl bromide (1.39 g, 0.007 mol) in (50 mL)
abs. ethanol was reﬂuxed for 24 h, the completion of the reac-
tion was monitored by TLC. It was then cooled to room tem-
perature and poured into ice-cold water, stirring for 30 min.
The solid was ﬁltered, washed with water, and then crystallized
from ethanol
2.6.1. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
phenyl-2,3-dihydro-1H-thiazole (6a)
(2.5 g, 81.2%); mp 220–222 C; IR (KBr) cm1 3273 (N–H),
3075 (C–H aromatic), 1626 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.56 (s, 2H, CH2), 8.13–8.16 (d, 1H, Ar–
H), 8.05–8.09 (d, 1H, Ar–H), 7.90–7.95 (d, 1H, Ar–H), 7.83–
7.86 (d, 1H, Ar–H), 7.75–7.79 (t, 1H, Ar–H), 7.66–7.71 (t,
1H, Ar–H), 7.59–7.62 (t, 1H, Ar–H), 7.52–7.55 (t, 1H, Ar–
H), 7.43–7.49 (m, 5H, Ar–H), 8.18 (s, 1H, proton of thiazole
ring), 9.21 (s, 1H, N–H, D2O exchangeable).
13C NMR
(400 MHz-DMSO-d6-ppm) d 10.99 (1C, CH2), 60.78, 61.63
(2C, 2C‚N), 130.98–137.09 (18C, aromatic carbons). Anal.
Found (calc.) for C28H33N3S (%): C, 75.79 (75.80); H, 7.52
(7.50); N, 9.45 (9.47); S, 7.24 (7.23).2.6.2. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
methoxyphenyl-2,3-dihydro-1H-thiazole (6b)
(0.75 g, 55%); mp 249–250 C; IR (KBr) cm1 3272 (N–H),
3072 (C–H aromatic), 1625 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.60 (s, 2H, CH2), 1.89 (s, 3H, OCH3),
8.08–8.11 (d, 1H, Ar–H), 7.97–8.03 (d, 1H, Ar–H), 7.88–7.91
(d, 1H, Ar–H), 7.80–7.83 (d, 1H, Ar–H), 7.71–7.74 (t, 1H,
Ar–H), 7.57–7.60 (t, 1H, Ar–H), 7.50–7.53 (t, 1H, Ar–H),
7.43–7.46 (t, 1H, Ar–H), 7.35–7.38 (m, 5H, Ar–H), 8.17 (s,
1H, proton of thiazole ring), 9.20 (s, 1H, NH, D2O exchange-
able). 13C NMR (400 MHz-DMSO-d6-ppm) d 11.08 (1C,
CH2), 14.69 (1C, OCH3), 61.57, 63.24 (2C, 2C‚N),
129.51138.79 (18C, aromatic carbons). Anal. Found (calc.)
for C29H35N3OS (%): C, 73.52 (73.53); H, 7.44 (7.45); N,
8.86 (8.87); S, 6.76 (6.77).
2.6.3. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
methylpheny-2,3-dihydro-1H-thiazole (6c)
(0.8 g, 64%); mp 245–248 C; IR (KBr) cm1 3275 (N–H),
3078 (C–H aromatic), 1626 (C‚N).1H NMR (400 MHz-
DMSO-d6-ppm) d 1.23 (s, 3H, CH3), 1.57 (s, 2H, CH2),
8.10–8.13 (d, 1H, Ar–H), 8.03–8.06 (d, 1H, Ar–H), 7.92–7.95
(d, 1H, Ar–H), 7.83–7.86 (d, 1H, Ar–H), 7.76–7.80 (t, 1H,
Ar–H), 7.69–7.73 (t, 1H, Ar–H), 7.60–7.64 (t, 1H, Ar–H),
7.52–7.55 (t, 1H, Ar–H), 7.44–7.47 (m, 5H, Ar–H), 8.16 (s,
1H, proton of thiazole ring), 9.22 (s, 1H, N–H, D2O exchange-
able). 13C NMR (400 MHz-DMSO-d6-ppm) d 8.07 (1C, CH3),
12.15 (1C, CH2), 62.39, 63.70 (2C, 2C‚N), 131.34–140.27
(18C, aromatic carbons). Anal. Found (calc.) for C29H35N3S
(%): C, 76.11 (76.10); H, 7.70 (7.71); N, 9.19 (9.18); S, 7.03
(7.01).
2.6.4. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
nitropheny-2,3-dihydro-1H-thiazole (6d)
(0.78 g, 52%); mp 240–242 C; IR (KBr) cm1 3236 (N–H),
3075 (C–H aromatic), 1624 (C‚N), 1545 and 1316 (NO2).
1H NMR (400 MHz-DMSO-d6-ppm) d 1.55 (s, 2H, CH2),
8.01–8.05 (d, 1H, Ar–H), 7.93–7.96 (d, 1H, Ar–H), 7.84–7.86
(d, 1H, Ar–H), 7.77–7.81 (d, 1H, Ar–H), 7.70–7.74 (t, 1H,
Ar–H), 7.64–7.66 (t, 1H, Ar–H), 7.58–7.61 (t, 1H, Ar–H),
7.50–7.53 (t, 1H, Ar–H), 7.46–7.49 (m, 5H, Ar–H), 8.14 (s,
1H, proton of thiazole ring), 9.25 (s, 1H, N–H, D2O exchange-
able). 13C NMR (400 MHz-DMSO-d6-ppm) d 11.68 (1C,
CH2), 61.30, 63.57 (2C, 2C‚N), 130.67–139.13 (18C, aromatic
carbons). Anal. Found (calc.) for C28H32N4O2S (%): C, 68.81
(68.82); H, 6.59 (6.60); N, 11.46 (11.47); S, 6.57 (6.56).
2.6.5. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
bromopheny-2,3-dihydro-1H-thiazole (6e)
(0.65 g, 50%); mp 255–257 C; IR (KBr) cm1 3274 (N–H),
3078 (C–H aromatic), 1628 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.57 (s, 2H, CH2), 8.11–8.15 (d, 1H, Ar–
H), 7.90–7.93 (d, 1H, Ar–H), 7.81–7.84 (d, 1H, Ar–H), 7.72–
7.75 (d, 1H, Ar–H), 7.65–7.68 (t, 1H, Ar–H), 7.60–7.63 (t,
1H, Ar–H), 7.53–7.56 (t, 1H, Ar–H), 7.43–7.45 (t, 1H, Ar–
H), 7.37–7.40 (m, 5H, Ar–H), 8.17 (s, 1H, proton of thiazole
ring), 9.15 (s, 1H, N–H, D2O exchangeable).
13C NMR
(400 MHz-DMSO-d6-ppm) d 10.90 (1C, CH2), 60.57, 61.89
(2C, 2C‚N), 128.93–130.88 (18C, aromatic carbons). Anal.
Found (calc.) for C28H32BrN3S (%): C, 64.37 (64.36); H,
6.16 (6.17); N, 8.05 (8.04); S, 6.15 (6.14).
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chloropheny-2,3-dihydro-1H-thiazole (6f)
(0.80 g, 54%); mp 267–269 C; IR (KBr) cm1 3270 (N–H),
3080(C–H aromatic), 1630 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.61 (s, 2H, CH2), 8.08–8.11 (d, 1H, Ar–
H), 7.99–8.02 (d, 1H, Ar–H), 7.90–7.93 (d, 1H, Ar–H), 7.85–
7.87 (d, 1H, Ar–H), 7.78–7.81 (t, 1H, Ar–H), 7.71–7.73 (t,
1H, Ar–H), 7.65–7.68 (t, 1H, Ar–H), 7.58–7.61 (t, 1H, Ar–
H), 7.52–7.55 (m, 5H, Ar–H), 8.15 (s, 1H, proton of thiazole
ring), 9.11 (s, 1H, N–H, D2O exchangeable).
13C NMR
(400 MHz-DMSO-d6-ppm) d 12.01 (1C, CH2), 60.76, 61.43
(2C, 2C‚N), 129.20–131.54 (18C, aromatic carbons). Anal.
Found (calc.) for C28H32ClN3S (%): C, 70.33 (70.34); H,
6.76 (6.75); N, 8.80 (8.79); S, 6.72 (6.71).
2.6.7. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-5-
hydroxypheny-2,3-dihydro-1H-thiazole (6g)
(0.78 g, 52.7%); mp 280–282 C; IR (KBr) cm1 3272 (N–H),
3079 (C–H aromatic), 1627 (C‚N). 1H NMR (400 MHz-
DMSO-d6-ppm) d 1.60 (s, 2H, CH2), 8.17–8.15 (d, 1H, Ar–
H), 8.04–8.07 (d, 1H, Ar–H), 7.94–7.97 (d, 1H, Ar–H), 7.87–
7.90 (d, 1H, Ar–H), 7.80–7.83 (t, 1H, Ar–H), 7.73–7.75 (t,
1H, Ar–H), 7.66–7.69 (t, 1H, Ar–H), 7.59–7.62 (t, 1H, Ar–
H), 7.52–7.56 (m, 5H, Ar–H), 8.19 (s, 1H, proton of thiazole
ring), 9.20 (s, 1H, N–H, D2O exchangeable), 12.31 (s, 1H,
O–H, D2O exchangeable).
13C NMR (400 MHz-DMSO-d6-
ppm) d 11.13 (1C, CH2), 60.98, 61.36 (2C, 2C‚N), 129.48–
131.05 (18C, aromatic carbons). Anal. Found (calc.) for
C28H33N3OS (%): C, 73.18 (73.16); H, 7.23 (7.24); N, 9.15
(9.14); S, 6.97 (6.98).
2.7. Synthesis of 2-(anthracen-9(10H)-ylidenehydrazono)-
thiazolidin-4-one (7)
To a mixture of compound 5 (5 g, 0.015 mol) and potassium
hydroxide (0.84 g, 0.015 mol) in (10 mL) abs. ethanol, chloro-
acetic acid (1.42 g, 0.015 mol) was added gradually. The reac-
tion mixture was reﬂuxed for 24 h, the completion of the
reaction was monitored by TLC. The cooled solution was di-
luted with 100 mL of ice-cold water and the precipitate ob-
tained was ﬁltered to yield 2.5 g of the crude product.
Crystallization from ethanol gave compound 7 as colorless
crystals (2.1 g, 44.6%); mp 270–273 C dec; IR (KBr) cm1
3321 (N–H), 3090 (C–H aromatic), 1657 (C‚O), 1625
(C‚N). 1H NMR (400 MHz-DMSO-d6-ppm) d 1.67 (s, 2H,
protons of anthracene ring), 2.04 (s, 2H, protons of thiazolid-
inone ring), 8.00–8.03 (d, 1H, Ar–H), 7.94–7.96 (d, 1H, Ar–H),
7.88–7.91 (d, 1H, Ar–H), 7.80–7.83 (d, 1H, Ar–H), 7.75–7.77
(t, 1H, Ar–H), 7.69–7.71 (t, 1H, Ar–H), 7.62–7.65 (t, 1H,
Ar–H), 7.54–7.57 (t, 1H, Ar–H), 8.89 (s, 1H, N–H, D2O
exchangeable). 13C NMR (400 MHz-DMSO-d6-ppm) d 10.79
(1C, CH2 of anthracene ring), 14.21 (1C, CH2 of thiazolidi-
none ring), 61.88 (1C, C‚N), 63.46 (1C, C‚N), 132.04–
139.15 (12C, aromatic carbons), 170.78 (1C, C‚O). Anal.
Found (calc.) for C22H29N3OS (%): C, 68.88 (68.89); H, 7.63
(7.62); N, 10.95 (10.96); S, 8.37 (8.36).
3. Results and discussion
3.1. Chemistry and characterization
The synthetic procedure adopted to obtain the target com-
pounds is depicted in Fig. 1. The starting compound anthrone1 was obtained from Aldrich Company and used directly with-
out further puriﬁcation. Thus, reﬂuxing of compound 1 with 4-
aminoantipyrine in boiling glacial acetic acid afforded the
Schiff base derivative 2. The oxidation of 2 with KMnO4
was studied with the aim of formation of benzimidazole deriv-
atives. Thus, it was oxidized using KMnO4 to give compound
3, and then cyclocondensation of compound 3 with o-phene-
lynediamine in boiling ethanol containing a catalytic amount
of HCl gave the benzimidazole derivative 4. Structures of these
products are based on analytical and spectral data. The IR
spectrum of compound 2 showed four characteristic absorp-
tion bands at 2987, 2865, 1685 and 1624 cm1 due to methyl,
C‚O and C‚N groups. While the characteristic IR absorp-
tion bands of compound 3 appeared at 1718, 1682 and
1623 cm1 due to C‚O and C‚N groups. On the other hand,
IR spectrum of compound 4 showed bands at 3356 and
1683 cm1 due to N–H and C‚O absorption bands. The 1H
NMR spectrum of compound 2 revealed the appearance of
two singlets at d 1.56 and 1.67 ppm assigned to two methyl
groups. The spectrum of compound 3 revealed one D2O-ex-
changable singlet at d 11.69 ppm assigned to one O–H proton,
in addition to one singlet at d 1.69 ppm due to one methyl pro-
ton. Furthermore, the 1H NMR spectrum of compound 4
showed one D2O-exchangable singlet at d 7.64 ppm due to
one N–H proton. The 13C NMR spectra of compounds 2, 3
and 4 showed signals at 167.43, 164.21 and 171.30, 169.23,
respectively, assigned to C‚O groups.
Recently, we have reported the reaction of anthrone with
L-histidine which represents a new, simple and efﬁcient syn-
thetic route for the synthesis of imidazole derivatives (Sali-
mon and Salih, 2010). Therefore, it was interesting to study
the reaction of 1 with thiosemicarbazide to yield compound
5, then cyclocondensation of 5 with p-substituted phenacyl
bromide and chloroacetic acid in boiling ethanol furnished
the thiazole derivatives, compounds 6a–g and 7, respectively.
The analytical and spectral data are in agreement with the
proposed structures. The IR spectrum of compound 5
showed two absorption bands at 3445 and 3350 cm1 due
to NH2 group beside one C‚N absorption bands at
1620 cm1. It’s 1H NMR revealed one D2O-exchangable sin-
glet at d 7.56 ppm due to NH2 protons. Furthermore, its
13C
NMR spectrum showed multiplet signals at 130.41–
136.25 ppm assigned to aromatic protons. On the other hand,
the IR spectra of compounds 6a–g showed characteristic
absorption bands at about 3275, 3080 and 1625 cm1 due
to N–H, aromatic protons and C‚N group. The 1H NMR
spectrum showed one D2O-exchangable singlet at d about
9.22 due to one thiazole N–H proton (Sarojini et al., 2010),
in addition to two singlets at d 1.57 assignable for methylene
protons of the anthracene. 13C NMR revealed signals at d
60.34 and 130.19–134.78 ppm due to C‚N group and aro-
matic carbons. Elemental analysis, IR, 1H NMR and 13C
NMR are in agreement with the proposed structures
Also, the structure of compound 7 was established on the
basis of its elemental analysis and spectral data. Its IR spec-
trum displayed an absorption band at 1657 cm1 due to
C‚O group. The 1H NMR spectrum showed one D2O-ex-
changable singlet at d 8.89 ppm due to N–H proton; beside this
a singlet signal appeared at d 2.02 ppm corresponding to the
thiazolidinone methylene group (Bondock et al., 2007). The
C‚O signal of the thiazolidinone ring appeared at d
170.78 ppm in 13C NMR spectrum.
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3.2.1. Antibacterial activity
The newly synthesized compounds were screened for their anti-
bacterial activity against Escherichia coli (ATTC-25922),
Staphylococcus aureus (ATTC-25923), Pseudomonas aerugin-
osa (ATTC-27853), and Bacillius subtilis (recultured) bacterial
stains by the disk-diffusion method (Cruickshank et al., 1975;
Collins, 1976). Disks measuring 6.25 mm in diameter were
punched from Whatman no. 1 ﬁlter paper. Batches of 100
disks were dispensed to each screw-capped bottle and sterilized
by dry heat at 140 C for an hour. The test compounds were
prepared with different concentrations using DMSO. One mil-
liliter containing 100 times the amount of chemical in each disk
was added to each bottle, which contained 100 discs. Disks of
each concentration were placed in triplicate in nutrient agar
medium seeded with fresh bacteria separately. The incubation
was carried out at 37 C for 24 h. Streptomycin was used as a
standard drug at a concentration of 10 lg/mL. Solvent andTable 1 Effect of synthesized compounds on human pathogenic ba
Compound Escherichia coli
(ATTC-25922)
Staphylococc
(ATTC-2592
1 – –
2 12 12
3 14 13
4 26 26
5 15 18
6a 20 18
6b – –
6c – 13
6d 28 25
6e 20 18
6f 19 19
6g 18 15
7 24 22
Standard (Streptomycine) 20 21
Zone of inhibition in millimeters.
Table 2 Effect of synthesized compounds on human pathogenic fu
Compound Aspergillus ﬂavus
(NICM No. 524)
Aspergillus fumigatus
(NCIM No. 902)
Pen
(rec
1 – – 10
2 25 22 19
3 15 16 21
4 20 15 18
5 – 17 –
6a 19 21 14
6b 20 18 17
6c 16 18 15
6d 25 24 20
6e 12 10 13
6f 15 18 23
6g 16 12 15
7 10 12 21
Standard (Flucanazole) 21 18 21
Zone of inhibition in millimeters.growth controls were kept and the zones of inhibition were
noted. The results of such studies are given in Table 1.
The above data showed that compound 2-(anthracen-
9(10H)-ylidenehydrazono)-5-nitrophenyl-2,3-dihydro-1H-thia-
zole 6d was the most potent compound, exhibited very good
activity against the four organisms. The compounds 4-(anthra-
cen-9(10H)-ylideneamino)-5-(1H-benzimidazol-2-yl)-1-methyl-
2-phenyl-1,2-dihydro-3H-pyrazol-3-one 4 and 2-(anthracen-
9(10H)-ylidenehydrazono)thiazolidin-4-one 7 exhibited very
good activity against E. coli and S. aureus. The remaining com-
pounds were found to have a slight or moderate activity
against the tested organisms and some of the compounds were
found to be inactive (indicated – sign).
3.2.2. Antifungal activity
Newly prepared compounds were screened for their antifungal
activity against Aspergillus ﬂavus (NICM No. 524), Aspergillus
fumigatus (NCIM No. 902), Candida albicans (NCIM No.
300), Penicillium marneffei (recultured), and Trichophytoncteria.
us aureus
3)
Pseudomonas aeruginosa
(ATTC-27853)
Bacillius subtilis
(recultured)
– –
13 11
17 15
22 23
8 –
17 18
13 13
14 14
24 26
17 18
20 21
12 12
20 20
24 24
ngi
icillium marneﬀei
ultured)
Candida Albicans
(NCIM No. 300)
Trichophyton Mentagrophytes
(recultured)
8 –
18 24
17 16
14 16
– –
16 18
16 19
18 19
17 19
18 –
16 17
20 14
17 16
20 19
Synthesis, spectral and biological evaluation of some new heterocyclic derivatives incorporating 405mentagrophytes (recultured) in DMSO by the serial plate dilu-
tion method (Khan, 1997; Varma, 1998). Sabouraud’s agar
media were prepared by dissolving peptone (1 g), D-glucose
(4 g), and agar (2 g) in distilled water (100 mL) and adjusting
the pH to 5.7. Normal saline was used to make a suspension
of the spore of fungal strain for lawning. A loopful of a partic-
ular fungal strain was transferred to 3 mL saline to get a sus-
pension of the corresponding species. Agar media (20 mL)
were poured into each petri dish. Excess suspension was dec-
anted and the plates were dried by placing in an incubator at
37 C for 1 h. Using agar punch, holes were made into each
agar and labeled. A control was also prepared in triplicate
and maintained at 37 C for 3–4 days. Antifungal activity
was determined by measuring the diameter of the inhibition
zone. Activity of each compound was compared with that of
ﬂucanazole as the standard.
The antifungal data showed that the newly prepared com-
pounds have moderate to good activity against the above-men-
tioned organisms. The compound 4-(anthracen-9(10H)-
ylideneamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-
3-one 2 exhibited very good activity against A. ﬂavus, A. fumig-
atus, and T. Mentagrophytes. Compound 2-(anthracen-9(10H)-
ylidenehydrazono)-5-nitrophenyl-2,3-dihydro-1H-thiazole 6d
showed very good activity toward A. ﬂavus and A. fumigatus.
The remaining compounds were found to have slight or moder-
ate activity against the tested organisms and some compounds
were found to be inactive (indicated – sign) (Table 2).
4. Conclusion
The main aim of the present study is to synthesize and investi-
gate the antimicrobial activity of new heterocyclic derivatives
containing pyrazole, benzimidazole, thiazole and thiazolidin-
4-one moieties with the hope of discovering new structures
serving as potential broad spectrum antimicrobial agents.
The antibacterial and antifungal data revealed that the com-
pounds 2–7 showed good to moderate antimicrobial activity.
Basically introduction of pyrazole moiety in the structure of
compound 2 has increased the antifungal activity compared
to the other. On the other hand, the presence of a pyrazole ring
together with a benzimidazole ring in compound 4 has a posi-
tive inﬂuence on antibacterial activity. Further, incorporation
of –NO2 group in the phenyl ring, compound 6d, increased
lipophilicity as well as a remarkably increased the antibacterial
and antifungal activity.Acknowledgments
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